Zenapax

DRUG4 trials

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS), Hoffmann-La Roche, Johns Hopkins University, Indiana University School of Medicine

Conditions

Kidney TransplantationMultiple SclerosisNewly Diagnosed With Type 1 DiabetesPatients Active and Listed for Lung Transplantation

Phase 2

Zenapax to Treat Multiple Sclerosis

CompletedNCT00001934

National Institute of Neurological Disorders and Stroke (NINDS)Multiple Sclerosis

Start: 1999-09-30End: 2008-09-30Updated: 2011-08-05

The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation

CompletedNCT00181142

Johns Hopkins UniversityPatients Active and Listed for Lung Transplantation

Start: 1999-10-31End: 2004-12-31Target: 60Updated: 2017-12-26

Prevention of Diabetes Progression Trial (PDPT)

CompletedNCT00198146

Indiana University School of MedicineNewly Diagnosed With Type 1 Diabetes

Start: 2000-07-31End: 2007-02-23Target: 40Updated: 2020-08-11

Phase 3

A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients

CompletedNCT00048152

Hoffmann-La RocheKidney Transplantation

Start: 2000-12-31End: 2006-03-31Updated: 2016-11-02

Related Papers

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

2009-04-01128 citations